ACUTE LYMPHOBLASTIC LEUKEMIA

This early-phase study tests a new type of cell therapy (CAR T cells) that targets two markers on leukemia cells (CD19 and CD22) in children and young adults up to age 21 whose leukemia has returned or not responded to standard treatments. The main goal is to find a safe dose and…

This study tests the safety and effectiveness of ponatinib in children aged 1 to under 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if the drug can shrink or control the cancer. About 70 childr…

This study tests a combination of two drugs—blinatumomab and ponatinib—along with chemotherapy in adults with a specific type of leukemia (Ph-positive ALL) that has come back or not responded to prior treatment. The goal is to see if this approach can improve response rates and s…

This early study tests a new treatment called LV009 injection in 10 adults with certain blood cancers (non-Hodgkin lymphoma or acute lymphoblastic leukemia) that have returned or not responded to standard therapy. The main goal is to check if the treatment is safe. Participants r…

This study is for children and young adults (ages 1-18) with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma. It tests a combination of two targeted immunotherapy drugs, inotuzumab and blinatumomab, given early in treatment. The goal is to see if this approach can…

This study is for people with a specific, high-risk form of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding two targeted drugs (olverembatinib or gecacitinib) to standard chemotherapy and venetoclax can help more patients achieve a deep rem…

This study tests a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) in 36 people aged 15-70 with relapsed or treatment-resistant Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. The goal is to see how many patients achieve complete…

This study tests two different methods to lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body, after a stem cell transplant. The trial includes 120 adults with acute leukemia or myelodysplastic syndrome (MDS) whos…

This study tests a special cell therapy called CAR T for children and young adults with a type of leukemia that has come back or not responded to treatment. Doctors will collect immune cells from the patient, modify them to attack cancer cells, and give them back after chemothera…

This study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants will take part, and the tr…

This study tests whether a targeted drug called inotuzumab ozogamicin works better than standard chemotherapy for children aged 1 to 17 with a first relapse of high-risk B-cell acute lymphoblastic leukemia. About 100 participants will receive either the new drug or standard thera…

This study is for people with certain blood cancers (like leukemia) who are getting a half-matched bone marrow transplant. Researchers are adding a dose of specially grown immune cells (gamma delta T-cells) after the transplant to see if it can kill any leftover cancer cells whil…

This study tests a new way to prepare stem cells for transplant in children and adults with blood cancers like leukemia. The method removes certain immune cells to lower the risk of graft-versus-host disease, a serious side effect. About 70 participants will receive the treatment…

This study tests whether a cord blood transplant, used as a first or second transplant, can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. About 71 participants will receive the transplant to see if it keeps them cancer-free for at le…

This early-phase study tests whether giving specially engineered immune cells (CAR T cells) along with a vaccine is safe and feasible for people with high-risk acute lymphoblastic leukemia who have already received a stem cell transplant from a matched related donor. The CAR T ce…

This study tests a new drug called bleximenib for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in the cancer cells. The study will first find the best dose and then check if it can safely help patien…

This study tests a two-step immunotherapy approach for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older, too frail for standard chemo, or whose cancer has returned. Participants will receive two targeted drugs in sequence: blinatumomab and inotuzumab ozogamic…

This study is testing whether a special type of immune cell therapy (CAR-T cells) can be successfully made right at the hospital for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The main goal is to see if the manufacturing proc…

This study tests a new way to prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers who receive a donor stem cell transplant. Researchers remove a specific type of immune cell (naive T cells) from the donor cells before transplant to red…

This study tests whether combining two drugs, blinatumomab and asciminib, can help control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults. About 40 participants will receive the combination to see if it is safe and effective. The goal is to mana…

This early-phase study tests a new way to prepare donor stem cells (called Orca-Q) for transplant in people with certain blood cancers like leukemia. The goal is to see if this engineered graft is safe and helps the body accept the new cells without serious side effects. About 30…

This early-phase trial is testing whether adding the targeted drug ruxolitinib to standard chemotherapy is safe for adolescents and young adults (ages 12-39) with a specific, high-risk form of acute lymphoblastic leukemia called Ph-like ALL. The study aims to find the best dose a…

This study tests a new type of immune cell therapy (CD19-CAR.p40-T) for people with blood cancers like lymphoma and leukemia that have come back or not responded to treatment. About 10 adults will receive their own immune cells that have been modified to better find and attack ca…

This early-phase study tests whether adding the drug calaspargase pegol to standard chemotherapy is safe and tolerable for young adults newly diagnosed with acute lymphoblastic leukemia. About 7 participants will receive the combination after their first round of chemo. The goal …

This study tests a combination of two targeted drugs (dasatinib and venetoclax) plus chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has come back or not responded to treatment. The goal is to find the safest dose and see how well the drugs shrin…

This early-phase study tests whether bone marrow from deceased donors can be safely used for people with blood cancers like leukemia and lymphoma. About 12 patients will receive a transplant after chemotherapy, and doctors will monitor for side effects and blood cell recovery for…

This study tests a treatment called KTE-X19, a type of CAR T-cell therapy, in adults with B-cell acute lymphoblastic leukemia (B-ALL) who are in remission but still have tiny amounts of cancer cells (minimal residual disease, or MRD). The goal is to see if this therapy can preven…

This study tests whether adding specially prepared donor immune cells can help children recover from stem cell transplants faster and avoid dangerous infections. Participants are children under 25 with high-risk blood cancers who have already received a transplant. The goal is to…

This study tests three different drug combinations to prevent graft-versus-host disease (GVHD) in 400 people with blood cancers receiving stem cells from unrelated donors. GVHD is a serious complication where donor cells attack the patient's body. The goal is to find which approa…

This study is for adults aged 18-65 newly diagnosed with acute lymphoblastic leukemia (ALL). It tests adding newer immunotherapy drugs (blinatumomab for B-cell ALL, isatuximab for T-cell ALL) to standard treatment, and refines when a stem cell transplant is needed. The goal is to…

This study offers a CAR T-cell therapy called brexucabtagene autoleucel to people with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially made treatment batch didn't pass quality checks. Participants must have a batch that still meets the study's safety stand…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests whether adding the drug ruxolitinib to the standard anti-rejection drugs tacrolimus and methotrexate can better prevent graft-versus-host disease (GVHD) in children and young adults (ages 2-22) receiving a bone marrow transplant for blood cancers like leukemia. G…

This study tests whether a second type of CAR T-cell therapy, targeting a protein called CD22, can prevent relapse in people with B-cell acute lymphoblastic leukemia who are in remission after initial CD19 CAR T-cell treatment. About 20 participants aged 3 to 65 will receive the …

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests whether a single infusion of obe-cabtagene autoleucel (obe-cel), a type of CAR T cell therapy, can help adults with B-cell acute lymphoblastic leukemia (ALL) stay in remission longer. Participants are in first complete remission with no detectable cancer cells af…

This early-phase trial tests whether a new type of CAR T cell therapy (UCD19) is safe and can work in adults with B-cell acute lymphoblastic leukemia (B-ALL) who are in first remission but still have tiny amounts of cancer cells (minimal residual disease). About 29 participants w…

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with certain types of acute leukemia that have come back or not responded to treatment. The trial includes about 52 participants aged 12 and older with specific genetic changes in their le…

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …

This early-stage study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells.…

This study tests whether adding a new targeted drug to standard chemotherapy helps adults with newly diagnosed acute T-lymphocytic leukemia live longer. About 154 participants will be randomly assigned to get either the new combo or chemo alone. The main goal is to see if the com…

This study tests a treatment called anti-CD19 CAR T-cell therapy for people with advanced B-cell leukemias or lymphomas that haven't responded to standard drugs. Participants' own immune cells are collected, modified to recognize and attack cancer cells, and then returned to the …

This study tests a new type of immunotherapy for children and young adults (ages 3-39) with B-cell cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to target…

This early-phase study tests the safety and best dose of revumenib, a drug that blocks a protein fueling leukemia growth, in 27 adults and children with specific genetic types of acute leukemia. Participants take revumenib after a stem cell transplant to help keep the cancer from…

This study tests a new drug called MK-1045 for people with a type of blood cancer (precursor B-cell acute lymphoblastic leukemia) that has returned or no longer responds to standard treatments. The study has two parts: first, finding a safe and tolerable dose, and second, checkin…

This early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…

This early-phase study tests a new stem cell treatment called Orca-T, combined with targeted radiation and chemotherapy, for people aged 60-75 with acute leukemias or myelodysplastic syndrome (MDS). The goal is to find the safest dose and see how well the body tolerates the treat…

This study tests a refined cord blood transplant method for people with high-risk blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to prepare the body, then drugs after to prevent rejection. The goal is to improve sur…

This study tests whether giving chemotherapy into the spinal fluid before and during blinatumomab treatment can prevent nerve-related side effects in adults with acute lymphoblastic leukemia. About 20 participants will receive the adjusted schedule. The goal is to keep the leukem…

This early-phase study is testing whether it is safe and possible to collect a patient's own stem cells and give them together with CAR T-cell therapy for blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain types of lymphoma…

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have come back or are hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells and give a drug called zoledronate after t…

This study tests if a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant for people with high-risk or hard-to-treat acute leukemia. About 48 adults aged 65 or younger will be randomly assigned to one of the two regimens. T…

This early-stage trial tests an experimental pill called MRX-2843 in teens and adults whose acute leukemia has returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 50 participants will take the pill daily in 2…

This study tests a new drug called revumenib in people with certain types of leukemia that have come back or not responded to other treatments. The goal is to find the best dose and see if it can help control the disease. About 447 adults with specific genetic changes (MLL/KMT2A …

This study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…

This study tests a second type of CAR T-cell therapy (CD22 CAR T) for children and young adults whose B-cell leukemia came back after standard CD19 CAR T treatment. About 20 participants will receive the new cells 28 to 42 days after the first therapy. The main goals are to check…

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests a 6-month virtual dietary education program (PEDALL) to prevent overweight and obesity in children and teens (ages 5-21) with acute lymphoblastic leukemia (ALL) during maintenance chemotherapy. The program is offered in English and Spanish and aims to keep partic…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This study looks at whether coloring mandalas before intrathecal chemotherapy (a spinal tap with chemo) can reduce fear and anxiety in children with leukemia. About 60 children aged 4 to 12 will participate. Researchers will measure their fear and anxiety using special scales bef…

This small study tests whether a physical activity program can help children (ages 5-17) with acute lymphoblastic leukemia maintain or regain muscle strength during early treatment. Kids who show signs of weakness after 5 weeks of treatment are randomly assigned to either the exe…

This study tests a program called MedSupport that helps families of children with acute lymphoblastic leukemia give their daily chemo medicine at home. Missing even a few doses can raise the risk of the cancer coming back. The program works with hospitals, doctors, and parents to…

This study looks at whether a home-based program of computer brain games and mindfulness exercises can improve thinking skills and emotional well-being in children and teens who have been treated for acute lymphoblastic leukemia. Participants, aged 8 to 18, will be randomly assig…

This study tests a mobile phone program that sends timely reminders and support to help teens and young adults (ages 14-29) with acute lymphoblastic leukemia take their oral chemotherapy as prescribed. The program is designed to adapt to each person's needs in real time. The main…

This study uses data from about 475 children with acute lymphoblastic leukemia (ALL) who received the drug Erwinase. Researchers will build a computer model to understand how the drug moves through the body, with the goal of finding the best dose to kill cancer cells while avoidi…

This study enrolls children and teens (ages 1-18) newly diagnosed with acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. The main goal is to collect enough information about each patient's cancer to determine their risk of the disease return…

This study looks at how the body absorbs, breaks down, and gets rid of a radioactive form of the drug bleximenib in 10 people with acute leukemia. Participants have a type of leukemia that has come back or not responded to other treatments. The goal is to understand the drug's pa…

This study will look back at the medical records of 18,000 children, adolescents, and young adults with cancer in low- and middle-income countries. The goal is to understand how often treatment fails or causes serious side effects, especially for acute lymphoblastic leukemia and …

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers, can cause early heart problems. Researchers will use ultrasound to check the heart function of 60 patients before and within a few days after treatment. The goal is to find out how often the…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to help researchers develop and improve blood tests that can detect many types of cancer early. Participants provide samples that are stored and later used to test new diagnostic methods.…

This study looks at whether finding leukemia stem cells in the blood and bone marrow can help predict if a child's leukemia will come back. It involves 283 children with acute myeloid leukemia. The goal is to improve relapse prediction so doctors can treat earlier and more effect…

This study looks at how bone marrow changes in people with acute leukemia after they receive total body irradiation and chemotherapy. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more, not to t…

This study looks at how young adult survivors of childhood leukemia feel about exercise. Researchers will use a special test and interviews to understand their emotions and thoughts about being active. The goal is to learn how to help them become more physically active in the fut…

This study aims to find genetic markers in saliva that could predict whether a person with newly diagnosed acute lymphoblastic leukemia will develop liver damage from the drug asparaginase. Researchers will collect saliva samples from 500 participants and track liver health durin…

This study is a large registry that gathers medical information and biological samples from 10,000 adults with acute lymphoblastic leukemia (ALL) and similar blood cancers. The goal is to learn how these diseases are diagnosed and treated in everyday practice, and to track patien…

This study looks at whether frequent blood and bone marrow tests can help doctors know if a child's leukemia will come back after CAR T-cell therapy. About 60 children and young adults aged 1 to 25 who have achieved remission after CAR T-cell therapy will be monitored every two w…

This study watches how the steroid dexamethasone moves through the body and affects bone health in 100 children (ages 1-17) being treated for acute lymphoblastic leukemia. Researchers will measure drug levels in blood and spinal fluid, track bone density with scans, and check for…

This study examines stored umbilical cord blood from 300 children who later developed leukemia. Researchers will look for the same genetic mutations found in the children's leukemia cells within their newborn cord blood. The goal is to understand how and when these cancer-causing…

This study is for people aged 8 to 25 who have survived a heart transplant, childhood leukemia, or were born with chronic lung disease (BPD). Researchers want to measure how the heart and lungs work during exercise using special breathing tests. The goal is to better understand w…

This study screens children and young adults (up to age 22) whose leukemia has returned or is difficult to treat. By testing their blood and bone marrow, doctors look for specific genetic markers to match them with the most promising experimental treatments. The goal is to improv…